Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
Transfus Clin Biol
; 28(3): 300-302, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1221046
ABSTRACT
The only effective way to provide individuals with herd immunity against the novel coronavirus [SARS-CoV-2] is to administer an effective vaccine that will help check the current pandemic status. In India, the central drugs standard control organization (CDSCO) has granted the emergency-use authorization [EUA] to three vaccines namely, Covishield (live vaccine, Oxford AstraZeneca, United Kingdom being manufactured by the Serum Institute of India), Covaxin (inactivated vaccine, Bharat Biotech, India) and Sputnik V (live vaccine, Gamaleya, Russia). However, there is a rising need for the efficacy of the vaccines to be proven against the "SARS-CoV-2 viral variants." Also, human plasma is polyclonal in nature with an inherent propensity to identify multiple epitopes of either an antigen or pathogen. With this context in mind, the researchers hypothesize that using COVID-19 convalescent plasma [CCP] harvested from the locally recovered individuals [i.e. potential CCP donors] may be particularly beneficial in combating not only the founder SARS-CoV-2 virus but also the geographically determined SARS-CoV-2 variants among the regionally affected COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pandemics
/
Geography, Medical
/
SARS-CoV-2
/
COVID-19
/
Antibodies, Viral
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Transfus Clin Biol
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS